Development of effective pharmaceutical interventions in acquired immunodeficiency syndrome (AIDS) is a high priority goal. About 10 million individuals worldwide are estimated to be infected with human immunodeficiency virus (HIV), the causative agent of AIDS, and the number of AIDS-related deaths continues to rise each year. Antiviral therapies which would halt progression of the disease are designed to selectively interfere with the ...
